Update shared on18 Aug 2025
Fair value Increased 5.68%The upward revision in Akeso’s price target reflects improved valuation sentiment, as indicated by a lower future P/E ratio, with the fair value rising to HK$125.08.
What's in the News
- Akeso continues to expand its late-stage oncology pipeline, with multiple first-in-human and pivotal Phase III trials initiated for its bispecific antibodies, particularly ivonescimab (PD-1/VEGF) targeting various indications including lung, colorectal, pancreatic cancers, and small cell lung cancer.
- Regulatory progress is strong: the NMPA accepted an sNDA submission for ivonescimab in combination with chemotherapy for first-line advanced squamous NSCLC, following prior filings in EGFR-TKI-resistant and PD-L1-positive subtypes.
- Cadonilimab (PD-1/CTLA-4 bispecific antibody) achieved a key regulatory milestone, securing NMPA approval for first-line persistent, recurrent, or metastatic cervical cancer, expanding its approved indications; ongoing registrational studies for cadonilimab aim at further cancer types, including advanced HCC.
- Akeso launched the first clinical trial of its bispecific ADC (AK146D1, targeting Trop2/Nectin4), positioning itself as the only company with two approved cancer bispecific immunotherapy antibodies and demonstrating leadership in the IO+ADC strategy globally.
- Board and shareholder meetings were scheduled to review interim results and grant equity incentives, reflecting continued corporate governance and talent retention.
Valuation Changes
Summary of Valuation Changes for Akeso
- The Consensus Analyst Price Target has risen from HK$118.36 to HK$125.08.
- The Future P/E for Akeso has fallen from 68.98x to 65.03x.
- The Discount Rate for Akeso remained effectively unchanged, moving only marginally from 6.81% to 6.89%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.